uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure's stock fell 41% after its Huntington’s disease gene therapy, AMT-130, showed a 44% slowing of disease progression at 48 months, missing statistical significance. Despite this, analysts and the company remain optimistic due to a strong secondary endpoint and questions about the primary endpoint's comparator data. The FDA's response to the new data remains uncertain.
How this was made
The 30-second read
Why it matters
The data release caused a sharp sell‑off, but analysts remain cautiously optimistic due to the secondary endpoint.
Market read
First disclosure of pivotal trial data directly moved the stock, influencing biotech sentiment.
What to watch
Missing external control data may bias results; FDA may still consider the secondary endpoint for accelerated approval.
Background
UniQure filed for accelerated FDA approval based on earlier data; the latest results raise questions about the primary endpoint's validity.
Market effects
Biotech sector may see broader caution on gene‑therapy programs pending FDA feedback.
European biotech investors could experience heightened volatility as UniQure is Dutch‑registered.
Potential slowdown in gene‑therapy investment sentiment across major markets.
Counterpoint
The robust secondary endpoint (61% TFC slowing) could sustain long‑term confidence and support a rebound.
Key entities
- CompanyUniQure
Biotech developing gene therapy AMT-130 for Huntington's disease.
- AnalystGuggenheim Securities
Provided commentary on trial data and secondary endpoint.
